Related Experiment Video
Updated: May 8, 2025

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
Published on: February 10, 2023
Use of Direct Oral Anticoagulation for Isolated Distal Deep Vein Thrombosis in Japanese Orthopedic Patients
Ayumi Omura1, Hiroyoshi Mori1, Masahiro Sasai1
1Division of Cardiology, Department of Medicine, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan.
Insights
Direct oral anticoagulants (DOAC) showed no significant difference in embolic or bleeding events for isolated distal deep vein thrombosis (DVT) in orthopedic patients. Careful risk assessment is crucial for managing these patients.
Area of Science:
- Vascular Medicine
- Pharmacology
- Orthopedic Surgery
Background:
- Direct oral anticoagulants (DOAC) are increasingly used for venous thromboembolism.
- Limited data exists on DOAC efficacy for isolated distal deep vein thrombosis (DVT).
Purpose of the Study:
- To evaluate the efficacy and safety of DOAC in hospitalized orthopedic patients with isolated distal DVT.
Main Methods:
- Retrospective study of 196 orthopedic patients diagnosed with isolated distal DVT (2016-2018).
- Patients were followed for 1 year, comparing outcomes between DOAC and non-DOAC groups.
- Embolic events included pulmonary embolism (PE) and DVT extension; bleeding events were classified by BARC criteria.
Main Results:
- 84% of patients received DOAC. Embolic events occurred in 1.5% of the DOAC group vs. 0% in the non-DOAC group (p=0.443).
- Bleeding events occurred in 5.1% of the DOAC group vs. 0% in the non-DOAC group (p=0.157).
- Most bleeding events (80%) were in patients with HAS-BLED scores ≥3.
Conclusions:
- No significant differences in embolic or bleeding events were observed between DOAC and non-DOAC groups in this retrospective analysis.
- Balancing thrombotic and bleeding risks is essential for managing isolated distal DVT.
Abstract:
Objectives: Although direct oral anticoagulants (DOAC) have become widely used, little is known about the efficacy of DOAC for isolated distal deep vein thrombosis (DVT). Methods: In-hospitalized orthopedic patients with isolated distal DVT who were diagnosed from 2016 to 2018 were enrolled and were followed for 1 year. Embolic events included symptomatic pulmonary embolism (PE) and DVT extension above the knee. Bleeding events were determined in the presence of bleeding academic research consortium (BARC) 2, 3 or 5 bleeding. Results: Of 196 orthopedic patients, 84% of patients (n = 164) received DOAC (DOAC+ group), whereas 16% of patients (n = 32) did not (DOAC- group). Cumulative incidence of embolic events was observed in 1.5% of the DOAC+ group and none of the DOAC- group (p = 0.443). Cumulative incidence of bleeding events was observed in 5.1% of the DOAC+ group and none of the DOAC- group (p = 0.157). The majority of bleeding events (80%) occurred in patients with HAS-BLED scores of 3 or greater. Conclusions: There were no significant differences in embolic events and bleeding events in retrospective data. Balancing thrombotic risk and bleeding risk remains to be key for isolated distal DVT.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia
One of the advantages of...

